<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01977209</url>
  </required_header>
  <id_info>
    <org_study_id>GTCA</org_study_id>
    <nct_id>NCT01977209</nct_id>
  </id_info>
  <brief_title>Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression</brief_title>
  <acronym>GTCA</acronym>
  <official_title>A Randomized, Double Blind, Placebo-controlled Multiple-center Phase III Trial of Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators' experimental study found that gossypol was the natural inhibitor of
      apyrimidinic endonuclease 1 (APE1) and clinical study observed that high expression of APE1
      was relative to the platinum-resistance in non-small cell lung cancer. Thus the purpose of
      this study is to find out whether gossypol can improve the sensitivity of cisplatin-based
      chemotherapy in the non-small cell lung cancer with apurinic apyrimidinic endonuclease 1
      (APE1) high expression
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>the first day of treatment to the date that disease progression is reported; assesed up to 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>the first day of treatment to death or last survival confirm date; assesed up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response rate</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>The ratio between the number of responders and number of patients assessable for tumor response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>the first date of treatment to 30 days after the last dose of study drug</time_frame>
    <description>Toxicity as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>the day before every cycle of chemotherapy; 30 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 75mg/m2/iv over 90min and cisplatin 75mg/m2/iv over 90min on day 1. Gossypol 20mg from day 1 to day 14. repeat Q 3weeks. Four cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Docetaxel 75mg/m2/iv over 90min and cisplatin 75mg/m2/iv over 90min on day 1. Placebo from day 1 to day 14. repeat Q 3weeks. Four cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gossypol</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic or cytologic diagnosis of NSCLC, Stage IIIB/IV.

          -  Males or females between 18 Years to 75 Years.

          -  No prior cisplatin-based chemotherapy, if the surgery or radiotherapy has been
             administered, the interval is at least above four weeks. The interval for targeted
             therapy such as EGFR TKI is above 2 weeks.

          -  Performance status of 0, 1 on the ECOG criteria. Expected survival is above three
             months.

          -  At least one unidimensional measurable lesion meeting Response Evaluation Criteria in
             Solid Tumors (RECIST. 2000).

          -  Patients can have the brain / meningeal metastasis history, but the metastasis must be
             treated by operation or radiotherapy), and clinically stable for at least 2 months.

          -  Adequate hematologic (neutrophil count &gt;= 1,500/uL, platelets &gt;= 100,000/uL), hepatic
             (transaminase =&lt; upper normal limit(UNL)x2.5, bilirubin level =&lt; UNLx1.5), and renal
             (creatinine =&lt; UNL) function.

          -  Patient compliance that allow adequate follow-up. Informed consent from patient or
             patient's relative.

          -  APE1 IHC (++ or +++).

          -  If female: childbearing potential either terminated by surgery, radiation, or
             menopause, or attenuated by use of an approved contraceptive method (intrauterine
             device [IUD], birth control pills, or barrier device) during and for 2 months after
             trial. If male, use of an approved contraceptive method during the study and 2 months
             afterwards. Females with childbearing potential must have a urine negative HCG test
             within 7 days prior to the study enrollment.

          -  No concomitant prescriptions including cyclosporin A, valproic acid, phenobarbital,
             phenytoin, ketoconazole.

        Exclusion Criteria:

          -  Inability to comply with protocol or study procedures.

          -  Medically uncontrolled serious heart, lung, neurological, psychological, metabolic
             disease.

          -  Second primary malignancy that is clinically detectable at the time of consideration
             for study enrollment.

          -  Pregnant or breast-feeding.

          -  Enrollment in other study within 30 days.

          -  Brain metastasis with symptoms.

          -  Hypokalemic periodic paralysis history.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Wang, PH.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Center, Daping Hospital, Third Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong Wang, PH.D.</last_name>
    <phone>86-23-68757151</phone>
    <email>dongwang64@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Daping Hospital, Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Wang, PH.D.</last_name>
      <phone>86-23-68757151</phone>
      <email>dongwang64@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Dong Wang, PH.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chongqing Zhongshan Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhixiang Yang, M.D.</last_name>
      <phone>13032372491</phone>
    </contact>
    <investigator>
      <last_name>Zhixiang Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fuling Central Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qi Zhou, M.D.</last_name>
      <phone>86-23-7222676</phone>
    </contact>
    <investigator>
      <last_name>Qi Zhou, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangjin Central Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debing Xiang, M.D.</last_name>
      <phone>86-13320336639</phone>
    </contact>
    <investigator>
      <last_name>Debing Xiang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Medical University Of Chongqing</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianquan Zhang, M.D.</last_name>
      <phone>86-23-63693000</phone>
    </contact>
    <investigator>
      <last_name>Xianquan Zhang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Three Gorges Central Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Biyong Ren</last_name>
      <phone>13896327099</phone>
    </contact>
    <investigator>
      <last_name>Biyong Ren, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC; IALT Bio Investigators. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006 Sep 7;355(10):983-91.</citation>
    <PMID>16957145</PMID>
  </reference>
  <reference>
    <citation>Kelley MR, Georgiadis MM, Fishel ML. APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1. Curr Mol Pharmacol. 2012 Jan;5(1):36-53. Review.</citation>
    <PMID>22122463</PMID>
  </reference>
  <reference>
    <citation>Wang D, Xiang DB, Yang XQ, Chen LS, Li MX, Zhong ZY, Zhang YS. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer. 2009 Dec;66(3):298-304. doi: 10.1016/j.lungcan.2009.02.019. Epub 2009 Mar 25.</citation>
    <PMID>19324449</PMID>
  </reference>
  <reference>
    <citation>Sonpavde G, Matveev V, Burke JM, Caton JR, Fleming MT, Hutson TE, Galsky MD, Berry WR, Karlov P, Holmlund JT, Wood BA, Brookes M, Leopold L. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol. 2012 Jul;23(7):1803-8. doi: 10.1093/annonc/mdr555. Epub 2011 Nov 23.</citation>
    <PMID>22112969</PMID>
  </reference>
  <reference>
    <citation>Ready N, Karaseva NA, Orlov SV, Luft AV, Popovych O, Holmlund JT, Wood BA, Leopold L. Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. J Thorac Oncol. 2011 Apr;6(4):781-5. doi: 10.1097/JTO.0b013e31820a0ea6.</citation>
    <PMID>21289522</PMID>
  </reference>
  <reference>
    <citation>Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2013 Jul 1;31(19):2404-12. doi: 10.1200/JCO.2012.46.9783. Epub 2013 May 20.</citation>
    <PMID>23690416</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2013</study_first_submitted>
  <study_first_submitted_qc>October 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2013</study_first_posted>
  <last_update_submitted>October 30, 2013</last_update_submitted>
  <last_update_submitted_qc>October 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Military Medical University</investigator_affiliation>
    <investigator_full_name>Dong Wang</investigator_full_name>
    <investigator_title>chief physician</investigator_title>
  </responsible_party>
  <keyword>NSCLC; Gossypol; APE1; Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Gossypol acetic acid</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Gossypol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

